Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, September 23, 2018 · 462,765,797 Articles · 3+ Million Readers

Fragile X Syndrome Market 2018-By Facilitate Decision-Making and Analyzing Market Data on 2026

Fragile X Syndrome Market 2018 Global Industry Analysis, Opportunities and Forecast To 2026

PUNE , INDIA, March 1, 2018 / -- Summary
Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability. FXS affects both men and women and the condition is also linked to other neurological and psychiatric disorders (CDC, 2017a). FXS is caused by an abnormal expansion in the number of the trinucleotide CGG repeats located in the 5' UTR in the fragile X mental retardation 1 gene (FMR1) at Xq27.3. Patients affected with FXS have more than 200 repeats of the CGG trinucleotide caused by full mutation of the FMR1 gene (NFXF, 2017; Saldarriaga et al., 2014).


In the 7MM, the diagnosed prevalent cases of FXS are expected to increase from 88,457 cases in 2016 to 91,919 cases in 2026, at an Annual Growth Rate (AGR) of 0.39% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed prevalent cases of FXS will increase from 36,942 cases in 2016 to 37,767 cases in 2026, at an AGR of 0.22%. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed prevalent cases of FXS during the forecast period except Germany and Japan, with AGRs of negative 0.22% and negative 0.31%, respectively, during the forecast period.

Epidemiologists developed the epidemiological forecast for the diagnosed prevalent cases of FXS segmented by age and sex in the 7MM. GlobalData epidemiologists used consistent methodology across the 7MM to ensure the comparability of the disease populations across the 7MM.

- The Fragile X Syndrome (FXS) EpiCast Report provides an overview of the risk factors and global trends of FXS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of FXS in these markets from 2016-2026. The prevalent cases are further segmented by age (0-19 years, 20-39 years, 40-59 years, 60-79 years, and 80 years and older) and sex.
- The FXS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The FXS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global FXS market.
- Quantify patient populations in the global FXS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for FXS therapeutics in each of the markets covered.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 5
3 Epidemiology 6


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire